Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phospholipid phosphatase-related protein type 5 (PLPPR5)
- Target
- PLPPR5
- Molecular classification
- Enzyme (phosphatase family; specifically a phospholipid phosphatase-related protein), Membrane protein (contains 6 transmembrane regions), Other (developmental/adaptational plasticity protein)
01
Overview
Phospholipid phosphatase-related protein type 5 (PLPPR5) is a membrane protein belonging to the phospholipid phosphatase-related (PLPPR) family, characterized by six transmembrane domains and evolutionary relation to phosphatidic acid phosphatases. It is predominantly expressed in the nervous system—especially in dendritic compartments postnatally—and is involved in promoting the formation of filopodia, neurite outgrowth, and dendritic spines. PLPPR5 acts independently of canonical CDC42/formin-mediated pathways and can reduce lysophosphatidic acid (LPA)-induced RhoA/ROCK signaling, thereby antagonizing neurite retraction. Mutations or altered expression are associated with specific neurodevelopmental syndromes such as Barre-Lieou syndrome and Bardet-Biedl syndrome 10. Currently, PLPPR5 is not directly targeted by any approved drugs but may be implicated in future research on neural repair, regeneration, or plasticity-related disorders.
- Other names
- Phospholipid phosphatase related 5LPPR5PAP2DPRG-5PRG5plasticity-related gene 5 proteinphosphatidic acid phosphatase type 2dlipid phosphate phosphatase-related protein type 5plasticity-related protein 5
02
Mechanism of action
Not currently targeted by drugs; overexpression studies implicate alteration of cytoskeletal and signaling pathways; possible modulation of Rho/ROCK pathway
03
Biological functions
Promotion of filopodia formationNeurite outgrowth and growth cone dynamicsModulation of RhoA/LPA signalingSynaptic and dendritic spine development
04
Disease associations
Neurodevelopmental/neuroplasticity-related disordersAssociated with Barre-Lieou syndromeAssociated with Bardet-Biedl syndrome 10Possible role in cancer cell migration/metastasis through the broader PLPPR family
05
Safety considerations
No notable therapeutic safety concerns documented; as a developmental and plasticity-related protein, manipulation in vivo could affect neural circuit formation or stability
06
Interacting drugs
None currently known or established in literature or major drug databases
07
Biomarkers
None currently established for patient selection or efficacy monitoring
Beyond the preview
Go deeper on Phospholipid phosphatase-related protein type 5 (PLPPR5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phospholipid phosphatase-related protein type 5 (PLPPR5).